Cargando…
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants of concern (VOCs) have negatively affected therapeutic use of s...
Ejemplares similares
-
Bebtelovimab-Induced Bradycardia Leading to Cardiac Arrest
por: Gearges, Christina, et al.
Publicado: (2022) -
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic
por: Nichols, Russell M, et al.
Publicado: (2022) -
The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Luo, Jie, et al.
Publicado: (2023) -
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
por: Dryden-Peterson, Scott, et al.
Publicado: (2022) -
Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19
por: Kapur, Rohan, et al.
Publicado: (2023)